Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

3351 results

Sort By:

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

Study ID: NCT07158489
Start Date: 2026-03-01
End Date: 2029-03-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

47

Intervention / Treatment

Gemcitabine + Ivonescimab

Sponsor

Swiss Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida

Study ID: NCT06607874
Start Date: 2025-12-16
End Date: 2026-09-16
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Non-Interventional Study

Sponsor

Mayo Clinic

Source: clinicaltrials.gov

Share:
Add to list

Effectiveness of Cingal™ for Improving Pain Scores and Function in Anterior Knee Pain

Study ID: NCT05714397
Start Date: 2026-04
End Date: 2026-11
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

24

Intervention / Treatment

Single

Sponsor

Banff Sport Medicine Foundation

Source: clinicaltrials.gov

Share:
Add to list

Quantitative Measurement of Plasma MTB Cell-free DNA Level

Study ID: NCT07170735
Start Date: 2026-01-01
End Date: 2027-06-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

85

Intervention / Treatment

Plasma MTB cfDNA assay

Sponsor

Chinese University of Hong Kong

Source: clinicaltrials.gov

Share:
Add to list

A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Study ID: NCT07221474
Start Date: 2025-12-16
End Date: 2031-05-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

180

Intervention / Treatment

V940

Pembrolizumab

Carboplatin

Paclitaxel

Nab-paclitaxel

Placebo

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

Study ID: NCT06987318
Start Date: 2026-02-15
End Date: 2028-05-07
Study Type

Interventional

Study Phase

Phase1

No. of Participants

40

Intervention / Treatment

Pers07-523LS

PGT121.414.LS

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Source: clinicaltrials.gov

Share:
Add to list

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Study ID: NCT07148050
Start Date: 2025-12-15
End Date: 2044-04-15
Study Type

Interventional

Study Phase

Phase1

No. of Participants

21

Intervention / Treatment

SC-CAR.GPC3xIL15.21 CAR T cells

Sponsor

Seattle Children's Hospital

Source: clinicaltrials.gov

Share:
Add to list

Effectiveness and Security Testing of a Mobile App

Study ID: NCT04519008
Start Date: 2026-10-01
End Date: 2028-09-15
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

80

Intervention / Treatment

Mobile app

Treatment as usual

Sponsor

Consorcio Sanitari del Maresme

Source: clinicaltrials.gov

Share:
Add to list

Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia

Study ID: NCT03378414
Start Date: 2025-12-31
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

45

Intervention / Treatment

Intravenous infusion

Intrathecal injection

umbilical cord mesenchymal stem cell

Sponsor

Sclnow Biotechnology Co., Ltd.

Source: clinicaltrials.gov

Share:
Add to list

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

Study ID: NCT07281833
Start Date: 2025-12-31
End Date: 2030-03
Study Type

Interventional

Study Phase

Phase3

No. of Participants

250

Intervention / Treatment

Capivasertib

Sponsor

West German Study Group

Source: clinicaltrials.gov

Share:
Add to list